Advertisement
U.S. markets closed

Bio-Techne Corporation (TECH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
70.39+0.97 (+1.40%)
At close: 04:00PM EDT
67.20 -3.19 (-4.53%)
After hours: 05:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close69.42
Open69.89
Bid70.34 x 1200
Ask70.41 x 900
Day's Range69.28 - 70.76
52 Week Range51.79 - 89.91
Volume1,122,748
Avg. Volume1,097,288
Market Cap11.065B
Beta (5Y Monthly)1.22
PE Ratio (TTM)50.64
EPS (TTM)1.39
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & Yield0.32 (0.45%)
Ex-Dividend DateFeb 09, 2024
1y Target Est80.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TECH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bio-Techne Corp
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • PR Newswire

    BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES

    Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

  • PR Newswire

    BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA

    Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.

  • InvestorPlace

    7 Biotech Stocks Ready to Ride the Sector’s Resurgence

    Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion. Second, a sector r